Products mentioned by Ben Zeskin
Products Ben Zeskin has mentioned or recommended across podcast appearances.
SignalCast may earn a small commission on purchases through these links — at no extra cost to you. As an Amazon Associate we earn from qualifying purchases.
Libtayo
by Regeneron
“Planned anti-PD-1 study with Regeneron's Libtayo in non-small cell lung cancer, with first patient dosing targeted for second-half 2025”
Mentioned on: The Bio Report · Outsmarting Resistance with RhythmAtabimetinib
Authorby Immuneering
“Immuneering CEO Ben Zeskind explains how the company's informatics-driven "deep cyclic inhibition" approach to MEK inhibition delivers intense daily pulses... Atabimetinib is novel composition-of-matter, with a US patent granted in summer 2024”
Mentioned on: The Bio Report · Outsmarting Resistance with Rhythm